Gilead inked a collaborative deal with Gritstone Oncology to develop a new vaccine-based immunotherapy with curative potential for HIV. This would mark the first “cure” for HIV, a disease which is typically managed and controlled with antiviral drug cocktails. The deal will see Gilead paying Gritstone $30 million in upfront cash as well as a $30 million equity investment. Gilead will also manage a Phase I trial for the vaccine.